Global Human Papillomavirus and Cytomegalovirus Therapeutics Market- Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning / Landscape Review & Global Market Size Forecast to 2032
5.21%
CAGR (2026-2032)
4.33 USD Bn.
Market Size
319
Report Pages
150
Market Tables
Overview
The Human Papillomavirus and Cytomegalovirus Therapeutics Market size was valued at USD 4.33 Billion in 2025 and the total Human Papillomavirus and Cytomegalovirus Therapeutics revenue is expected to grow at a CAGR of 5.21% from 2025 to 2032, reaching nearly USD 6.18 Billion by 2032.
Human Papillomavirus and Cytomegalovirus Therapeutics Market Drivers and Restrains:
The Human papillomavirus (HPV) and Cytomegalovirus (CMV) are viral pathogens, which are causes by the sexually transmitted infection. HPV is a different virus than HIV (Human Immunodeficiency Virus) and HSV (Herpes Simplex Virus). HPV is a major cause of cervical, vulva, vagina, penis, anus, mouth, and throat cancer.
To know about the Research Methodology :- Request Free Sample Report
CMV is the most common herpes virus infection, which can be spread through sexual and non-sexual contact with body secretions (fluids) such as saliva, semen, breast milk, and urine.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The market has driven by such factors are increasing prevalence of HPV and CMV infections in developing and underdeveloped economies, global age-specific incidence of cervical cancer and high global demand for low-cost generic drugs. Rising number of sexually transferred infections is one of major drivers for the market growth. For instance, according to the report of World Health Organization's (WHO), in 2018, over xx million women suffer from HPV infection worldwide and over xx million people suffer from sexually transmitted infections (STIs) globally.
Severe side-effects of HPV vaccines, lack of awareness in developing areas is declining the diagnostic rates and annual number of new cases of cervical cancer by age group are hampering the HPV therapeutics market growth at global level. Biologics and drugs with low toxicity, short treatment regime against HPV infections and health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics.
Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures are hindering the CMV therapeutics market growth at global level. Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine are provided to the lucrative opportunity in the CMV therapeutics market.
Human Papillomavirus and Cytomegalovirus Therapeutics Market Segmentation Analysis:
Based on the HPV drug class, the human papillomavirus and cytomegalovirus therapeutics market has been segmented into Immunomodulators, Keratolytic agents, Anti-neoplastic agents and Sinecatechins. Immunomodulators segment account for the largest share of the HPV therapeutics market in 2018. The Sinecatechins segment is expected to grow at the largest CAGR of xx% during the forecast period.
Based on the application, the genital warts segment held the dominant market share in terms of revenue generation, due to higher number of HPV strains leading to genital warts which are easily transmitted through sexual contact. Genital warts soft progresses that act on the genitals, Genital warts can cause lots of pain, discomfort, and itching. Increasing demand for minimally invasive surgical procedures in genital warts treatment will drive the market growth. Dry therapeutic pipeline and serious threat from substitutes such as Cryotherapy and laser therapy have made the market less attractive.
Human Papillomavirus and Cytomegalovirus Therapeutics Market Regional Analysis:
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the market in 2018 owing to increasing initiatives for treatment of cervical cancer by health regulatory authorities in this region. For example, in June 2018, the U.S. Food and Drug Administration announced approval of Keytruda (Contains-Pembrolizumab), which is refer for the treatment of PD-L1–positive cervical cancer. The market in Europe is expected to expand at a high CAGR of xx% during the forecast period due to increasing approval activities by European regulatory authorities. European Medicines Agency approved marketing authorization of PreVymis (Letermovir) in the European Union. It is an anti-viral medicine, which is used for the prevention of CMV infections.
Human Papillomavirus and Cytomegalovirus Therapeutics Market Competitive landscape
Major Key players operating in this market are Allergan, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings and Merck Sharp & Dohme. Manufacturers in the human papillomavirus and cytomegalovirus therapeutics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present comprehensive analysis of market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report.
External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding market dynamics, structure by analyzing the market segments, and project the market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the market make the report investor’s guide.
Scope of the Human Papillomavirus and Cytomegalovirus Therapeutics Market: Inquire before buying
| Global Human Papillomavirus and Cytomegalovirus Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 4.33 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 5.21% | Market Size in 2032: | USD 6.18 Bn. |
| Segments Covered: | by HPV Drug Class | Immunomodulators Keratolytic Agents Anti-neoplastic Agents Sinecatechins |
|
| by HPV Application | Genital Warts Genital Cancer Epidermodysplasia Verrucifdormis Oral Papillomas |
||
| by CMV Antiviral Drug | Ganciclovir/Valganciclovir Foscarnet Cidofovir |
||
| by CMV Application | CMV Retinitis Pneumonia Gastrointestinal ulcers Encephalitis |
||
Human Papillomavirus and Cytomegalovirus Therapeutics Market, by Region:
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Human Papillomavirus and Cytomegalovirus Therapeutics Market, Key Players are:
1.Allergan
2.Bausch Health
3.GlaxoSmithKline
4.Lee's Pharmaceutical Holdings
5.Merck Sharp & Dohme
6.Fougera Pharmaceuticals
7.Clinigen Group plc.
8.Perrigo Company plc.
9.Roche Holding AG
10.Biotest AG
11.Fresenius Kabi
12.Valeant Pharmaceuticals
13.AbbVie, Inc.
14.Mylan N.V.
15.Teva Pharmaceutical Industries Ltd.
16.Clinigen Group plc
17.Cipla Inc.
Frequently Asked questions
1. What is the market size of the Global Human Papillomavirus and Cytomegalovirus Therapeutics Market in 2025?
Ans. The market size market in 2025 was USD 4.33 Billion.
2. What are the different segments of the Global Human Papillomavirus and Cytomegalovirus Therapeutics Market?
Ans. The market is divided into HPV Drug Class, HPV Application, CMV Antiviral Drug and CMV Application.
3. What is the study period of this market?
Ans. The Global market will be studied from 2025 to 2032.
4. Which region is expected to hold the highest Global Human Papillomavirus and Cytomegalovirus Therapeutics Market share?
Ans. The Asia Pacific dominates the market share in the market.
5. What is the Forecast Period of Global Human Papillomavirus and Cytomegalovirus Therapeutics Market?
Ans. The Forecast Period of the market is 2026-2032 in the market.
Table of Contents
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
6.1. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by HPV Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Drug Class
7.4. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size (US$ Bn) Forecast, by HPV Drug Class
7.5. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by HPV Drug Class
7.6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis, by HPV Drug Class
8. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by HPV Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Application
8.4. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size (US$ Bn) Forecast, by HPV Application
8.5. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by HPV Application
8.6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis, by HPV Application
9. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by CMV Antiviral Drug
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Antiviral Drug
9.4. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size (US$ Bn) Forecast, by CMV Antiviral Drug
9.5. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by CMV Antiviral Drug
9.6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis, by CMV Antiviral Drug
10. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by CMV Application
10.1. Introduction and Definition
10.2. Key Findings
10.3. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Application
10.4. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size (US$ Bn) Forecast, by CMV Application
10.5. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by CMV Application
10.6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis, by CMV Application
11. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by Region
11.1. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by Region
11.2. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Size (US$ Bn) Forecast, by Region
11.3. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Region
12. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis
12.1. Key Findings
12.2. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Overview
12.3. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Drug Class
12.4. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
12.4.1. Immunomodulators
12.4.2. Keratolytic Agents
12.4.3. Anti-neoplastic Agents
12.4.4. Sinecatechins
12.5. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Application
12.6. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
12.6.1. Genital Warts
12.6.2. Genital Cancer
12.6.3. Epidermodysplasia Verrucifdormis
12.6.4. Oral Papillomas
12.7. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Antiviral Drug
12.8. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
12.8.1. Ganciclovir/Valganciclovir
12.8.2. Foscarnet
12.8.3. Cidofovir
12.9. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Application
12.10. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
12.10.1. CMV Retinitis
12.10.2. Pneumonia
12.10.3. Gastrointestinal ulcers
12.10.4. Encephalitis
12.11. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by Country
12.12. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by Country
12.12.1. U.S.
12.12.2. Canada
12.13. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by Country
12.14. U.S. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
12.14.1. Immunomodulators
12.14.2. Keratolytic Agents
12.14.3. Anti-neoplastic Agents
12.14.4. Sinecatechins
12.15. U.S. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
12.15.1. Genital Warts
12.15.2. Genital Cancer
12.15.3. Epidermodysplasia Verrucifdormis
12.15.4. Oral Papillomas
12.16. U.S. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
12.16.1. Ganciclovir/Valganciclovir
12.16.2. Foscarnet
12.16.3. Cidofovir
12.17. U.S. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
12.17.1. CMV Retinitis
12.17.2. Pneumonia
12.17.3. Gastrointestinal ulcers
12.17.4. Encephalitis
12.18. Canada Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
12.18.1. Immunomodulators
12.18.2. Keratolytic Agents
12.18.3. Anti-neoplastic Agents
12.18.4. Sinecatechins
12.19. Canada Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
12.19.1. Genital Warts
12.19.2. Genital Cancer
12.19.3. Epidermodysplasia Verrucifdormis
12.19.4. Oral Papillomas
12.20. Canada Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
12.20.1. Ganciclovir/Valganciclovir
12.20.2. Foscarnet
12.20.3. Cidofovir
12.21. Canada Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
12.21.1. CMV Retinitis
12.21.2. Pneumonia
12.21.3. Gastrointestinal ulcers
12.21.4. Encephalitis
12.22. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis
12.22.1. By HPV Drug Class
12.22.2. By HPV Application
12.22.3. By CMV Antiviral Drug
12.22.4. By CMV Application
12.23. PEST Analysis
12.24. Key Trends
12.25. Key Developments
13. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis
13.1. Key Findings
13.2. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Overview
13.3. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Drug Class
13.4. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.4.1. Immunomodulators
13.4.2. Keratolytic Agents
13.4.3. Anti-neoplastic Agents
13.4.4. Sinecatechins
13.5. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Application
13.6. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.6.1. Genital Warts
13.6.2. Genital Cancer
13.6.3. Epidermodysplasia Verrucifdormis
13.6.4. Oral Papillomas
13.7. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Antiviral Drug
13.8. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.8.1. Ganciclovir/Valganciclovir
13.8.2. Foscarnet
13.8.3. Cidofovir
13.9. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Application
13.10. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.10.1. CMV Retinitis
13.10.2. Pneumonia
13.10.3. Gastrointestinal ulcers
13.10.4. Encephalitis
13.11. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by Country
13.12. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by Country
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by Country
13.14. Germany Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.14.1. Immunomodulators
13.14.2. Keratolytic Agents
13.14.3. Anti-neoplastic Agents
13.14.4. Sinecatechins
13.15. Germany Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.15.1. Genital Warts
13.15.2. Genital Cancer
13.15.3. Epidermodysplasia Verrucifdormis
13.15.4. Oral Papillomas
13.16. Germany Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.16.1. Ganciclovir/Valganciclovir
13.16.2. Foscarnet
13.16.3. Cidofovir
13.17. Germany Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.17.1. CMV Retinitis
13.17.2. Pneumonia
13.17.3. Gastrointestinal ulcers
13.17.4. Encephalitis
13.18. U.K. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.18.1. Immunomodulators
13.18.2. Keratolytic Agents
13.18.3. Anti-neoplastic Agents
13.18.4. Sinecatechins
13.19. U.K. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.19.1. Genital Warts
13.19.2. Genital Cancer
13.19.3. Epidermodysplasia Verrucifdormis
13.19.4. Oral Papillomas
13.20. U.K. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.20.1. Ganciclovir/Valganciclovir
13.20.2. Foscarnet
13.20.3. Cidofovir
13.21. U.K. Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.21.1. CMV Retinitis
13.21.2. Pneumonia
13.21.3. Gastrointestinal ulcers
13.21.4. Encephalitis
13.22. France Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.22.1. Immunomodulators
13.22.2. Keratolytic Agents
13.22.3. Anti-neoplastic Agents
13.22.4. Sinecatechins
13.23. France Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.23.1. Genital Warts
13.23.2. Genital Cancer
13.23.3. Epidermodysplasia Verrucifdormis
13.23.4. Oral Papillomas
13.24. France Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.24.1. Ganciclovir/Valganciclovir
13.24.2. Foscarnet
13.24.3. Cidofovir
13.25. France Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.25.1. CMV Retinitis
13.25.2. Pneumonia
13.25.3. Gastrointestinal ulcers
13.25.4. Encephalitis
13.26. Italy Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.26.1. Immunomodulators
13.26.2. Keratolytic Agents
13.26.3. Anti-neoplastic Agents
13.26.4. Sinecatechins
13.27. Italy Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.27.1. Genital Warts
13.27.2. Genital Cancer
13.27.3. Epidermodysplasia Verrucifdormis
13.27.4. Oral Papillomas
13.28. Italy Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.28.1. Ganciclovir/Valganciclovir
13.28.2. Foscarnet
13.28.3. Cidofovir
13.29. Italy Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.29.1. CMV Retinitis
13.29.2. Pneumonia
13.29.3. Gastrointestinal ulcers
13.29.4. Encephalitis
13.30. Spain Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.30.1. Immunomodulators
13.30.2. Keratolytic Agents
13.30.3. Anti-neoplastic Agents
13.30.4. Sinecatechins
13.31. Spain Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.31.1. Genital Warts
13.31.2. Genital Cancer
13.31.3. Epidermodysplasia Verrucifdormis
13.31.4. Oral Papillomas
13.32. Spain Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.32.1. Ganciclovir/Valganciclovir
13.32.2. Foscarnet
13.32.3. Cidofovir
13.33. Spain Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.33.1. CMV Retinitis
13.33.2. Pneumonia
13.33.3. Gastrointestinal ulcers
13.33.4. Encephalitis
13.34. Rest of Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
13.34.1. Immunomodulators
13.34.2. Keratolytic Agents
13.34.3. Anti-neoplastic Agents
13.34.4. Sinecatechins
13.35. Rest of Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
13.35.1. Genital Warts
13.35.2. Genital Cancer
13.35.3. Epidermodysplasia Verrucifdormis
13.35.4. Oral Papillomas
13.36. Rest of Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
13.36.1. Ganciclovir/Valganciclovir
13.36.2. Foscarnet
13.36.3. Cidofovir
13.37. Rest Of Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
13.37.1. CMV Retinitis
13.37.2. Pneumonia
13.37.3. Gastrointestinal ulcers
13.37.4. Encephalitis
13.38. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis
13.38.1. By HPV Drug Class
13.38.2. By HPV Application
13.38.3. By CMV Antiviral Drug
13.38.4. By CMV Application
13.39. PEST Analysis
13.40. Key Trends
13.41. Key Developments
14. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis
14.1. Key Findings
14.2. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Overview
14.3. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Drug Class
14.4. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
14.4.1. Immunomodulators
14.4.2. Keratolytic Agents
14.4.3. Anti-neoplastic Agents
14.4.4. Sinecatechins
14.5. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Application
14.6. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
14.6.1. Genital Warts
14.6.2. Genital Cancer
14.6.3. Epidermodysplasia Verrucifdormis
14.6.4. Oral Papillomas
14.7. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Antiviral Drug
14.8. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
14.8.1. Ganciclovir/Valganciclovir
14.8.2. Foscarnet
14.8.3. Cidofovir
14.9. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Application
14.10. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
14.10.1. CMV Retinitis
14.10.2. Pneumonia
14.10.3. Gastrointestinal ulcers
14.10.4. Encephalitis
14.11. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by Country
14.12. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by Country
14.12.1. China
14.12.2. India
14.12.3. Japan
14.12.4. ASEAN
14.12.5. Rest of Asia Pacific
14.13. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by Country
14.14. China Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
14.14.1. Immunomodulators
14.14.2. Keratolytic Agents
14.14.3. Anti-neoplastic Agents
14.14.4. Sinecatechins
14.15. China Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
14.15.1. Genital Warts
14.15.2. Genital Cancer
14.15.3. Epidermodysplasia Verrucifdormis
14.15.4. Oral Papillomas
14.16. China Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
14.16.1. Ganciclovir/Valganciclovir
14.16.2. Foscarnet
14.16.3. Cidofovir
14.17. China Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
14.17.1. CMV Retinitis
14.17.2. Pneumonia
14.17.3. Gastrointestinal ulcers
14.17.4. Encephalitis
14.18. India Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
14.18.1. Immunomodulators
14.18.2. Keratolytic Agents
14.18.3. Anti-neoplastic Agents
14.18.4. Sinecatechins
14.19. India Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
14.19.1. Genital Warts
14.19.2. Genital Cancer
14.19.3. Epidermodysplasia Verrucifdormis
14.19.4. Oral Papillomas
14.20. India Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
14.20.1. Ganciclovir/Valganciclovir
14.20.2. Foscarnet
14.20.3. Cidofovir
14.21. India Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
14.21.1. CMV Retinitis
14.21.2. Pneumonia
14.21.3. Gastrointestinal ulcers
14.21.4. Encephalitis
14.22. Japan Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
14.22.1. Immunomodulators
14.22.2. Keratolytic Agents
14.22.3. Anti-neoplastic Agents
14.22.4. Sinecatechins
14.23. Japan Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
14.23.1. Genital Warts
14.23.2. Genital Cancer
14.23.3. Epidermodysplasia Verrucifdormis
14.23.4. Oral Papillomas
14.24. Japan Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
14.24.1. Ganciclovir/Valganciclovir
14.24.2. Foscarnet
14.24.3. Cidofovir
14.25. Japan Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
14.25.1. CMV Retinitis
14.25.2. Pneumonia
14.25.3. Gastrointestinal ulcers
14.25.4. Encephalitis
14.26. ASEAN Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
14.26.1. Immunomodulators
14.26.2. Keratolytic Agents
14.26.3. Anti-neoplastic Agents
14.26.4. Sinecatechins
14.27. ASEAN Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
14.27.1. Genital Warts
14.27.2. Genital Cancer
14.27.3. Epidermodysplasia Verrucifdormis
14.27.4. Oral Papillomas
14.28. ASEAN Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
14.28.1. Ganciclovir/Valganciclovir
14.28.2. Foscarnet
14.28.3. Cidofovir
14.29. ASEAN Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
14.29.1. CMV Retinitis
14.29.2. Pneumonia
14.29.3. Gastrointestinal ulcers
14.29.4. Encephalitis
14.30. Rest of Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
14.30.1. Immunomodulators
14.30.2. Keratolytic Agents
14.30.3. Anti-neoplastic Agents
14.30.4. Sinecatechins
14.31. Rest of Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
14.31.1. Genital Warts
14.31.2. Genital Cancer
14.31.3. Epidermodysplasia Verrucifdormis
14.31.4. Oral Papillomas
14.32. Rest of Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
14.32.1. Ganciclovir/Valganciclovir
14.32.2. Foscarnet
14.32.3. Cidofovir
14.33. Rest of Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
14.33.1. CMV Retinitis
14.33.2. Pneumonia
14.33.3. Gastrointestinal ulcers
14.33.4. Encephalitis
14.34. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis
14.34.1. By HPV Drug Class
14.34.2. By HPV Application
14.34.3. By CMV Antiviral Drug
14.34.4. By CMV Application
14.35. PEST Analysis
14.36. Key Trends
14.37. Key Developments
15. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Overview
15.3. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Drug Class
15.4. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
15.4.1. Immunomodulators
15.4.2. Keratolytic Agents
15.4.3. Anti-neoplastic Agents
15.4.4. Sinecatechins
15.5. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Application
15.6. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
15.6.1. Genital Warts
15.6.2. Genital Cancer
15.6.3. Epidermodysplasia Verrucifdormis
15.6.4. Oral Papillomas
15.7. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Antiviral Drug
15.8. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
15.8.1. Ganciclovir/Valganciclovir
15.8.2. Foscarnet
15.8.3. Cidofovir
15.9. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Application
15.10. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
15.10.1. CMV Retinitis
15.10.2. Pneumonia
15.10.3. Gastrointestinal ulcers
15.10.4. Encephalitis
15.11. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by Country
15.12. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by Country
15.12.1. GCC
15.12.2. South Africa
15.12.3. Rest of Middle East & Africa
15.13. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by Country
15.14. GCC Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
15.14.1. Immunomodulators
15.14.2. Keratolytic Agents
15.14.3. Anti-neoplastic Agents
15.14.4. Sinecatechins
15.15. GCC Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
15.15.1. Genital Warts
15.15.2. Genital Cancer
15.15.3. Epidermodysplasia Verrucifdormis
15.15.4. Oral Papillomas
15.16. GCC Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
15.16.1. Ganciclovir/Valganciclovir
15.16.2. Foscarnet
15.16.3. Cidofovir
15.17. GCC Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
15.17.1. CMV Retinitis
15.17.2. Pneumonia
15.17.3. Gastrointestinal ulcers
15.17.4. Encephalitis
15.18. South Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
15.18.1. Immunomodulators
15.18.2. Keratolytic Agents
15.18.3. Anti-neoplastic Agents
15.18.4. Sinecatechins
15.19. South Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
15.19.1. Genital Warts
15.19.2. Genital Cancer
15.19.3. Epidermodysplasia Verrucifdormis
15.19.4. Oral Papillomas
15.20. South Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
15.20.1. Ganciclovir/Valganciclovir
15.20.2. Foscarnet
15.20.3. Cidofovir
15.21. South Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
15.21.1. CMV Retinitis
15.21.2. Pneumonia
15.21.3. Gastrointestinal ulcers
15.21.4. Encephalitis
15.22. Rest of Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
15.22.1. Immunomodulators
15.22.2. Keratolytic Agents
15.22.3. Anti-neoplastic Agents
15.22.4. Sinecatechins
15.23. Rest of Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
15.23.1. Genital Warts
15.23.2. Genital Cancer
15.23.3. Epidermodysplasia Verrucifdormis
15.23.4. Oral Papillomas
15.24. Rest of Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
15.24.1. Ganciclovir/Valganciclovir
15.24.2. Foscarnet
15.24.3. Cidofovir
15.25. Rest of Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
15.25.1. CMV Retinitis
15.25.2. Pneumonia
15.25.3. Gastrointestinal ulcers
15.25.4. Encephalitis
15.26. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis
15.26.1. By HPV Drug Class
15.26.2. By HPV Application
15.26.3. By CMV Antiviral Drug
15.26.4. By CMV Application
15.27. PEST Analysis
15.28. Key Trends
15.29. Key Developments
16. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis
16.1. Key Findings
16.2. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Overview
16.3. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Drug Class
16.4. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
16.4.1. Immunomodulators
16.4.2. Keratolytic Agents
16.4.3. Anti-neoplastic Agents
16.4.4. Sinecatechins
16.5. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by HPV Application
16.6. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
16.6.1. Genital Warts
16.6.2. Genital Cancer
16.6.3. Epidermodysplasia Verrucifdormis
16.6.4. Oral Papillomas
16.7. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Antiviral Drug
16.8. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
16.8.1. Ganciclovir/Valganciclovir
16.8.2. Foscarnet
16.8.3. Cidofovir
16.9. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by CMV Application
16.10. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
16.10.1. CMV Retinitis
16.10.2. Pneumonia
16.10.3. Gastrointestinal ulcers
16.10.4. Encephalitis
16.11. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Value Share Analysis, by Country
16.12. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by Country
16.12.1. Brazil
16.12.2. Mexico
16.12.3. Rest of South America
16.13. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis, by Country
16.14. Brazil Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
16.14.1. Immunomodulators
16.14.2. Keratolytic Agents
16.14.3. Anti-neoplastic Agents
16.14.4. Sinecatechins
16.15. Brazil Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
16.15.1. Genital Warts
16.15.2. Genital Cancer
16.15.3. Epidermodysplasia Verrucifdormis
16.15.4. Oral Papillomas
16.16. Brazil Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
16.16.1. Ganciclovir/Valganciclovir
16.16.2. Foscarnet
16.16.3. Cidofovir
16.17. Brazil Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
16.17.1. CMV Retinitis
16.17.2. Pneumonia
16.17.3. Gastrointestinal ulcers
16.17.4. Encephalitis
16.18. Mexico Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
16.18.1. Immunomodulators
16.18.2. Keratolytic Agents
16.18.3. Anti-neoplastic Agents
16.18.4. Sinecatechins
16.19. Mexico Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
16.19.1. Genital Warts
16.19.2. Genital Cancer
16.19.3. Epidermodysplasia Verrucifdormis
16.19.4. Oral Papillomas
16.20. Mexico Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
16.20.1. Ganciclovir/Valganciclovir
16.20.2. Foscarnet
16.20.3. Cidofovir
16.21. Mexico Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
16.21.1. CMV Retinitis
16.21.2. Pneumonia
16.21.3. Gastrointestinal ulcers
16.21.4. Encephalitis
16.22. Rest of South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Drug Class
16.22.1. Immunomodulators
16.22.2. Keratolytic Agents
16.22.3. Anti-neoplastic Agents
16.22.4. Sinecatechins
16.23. Rest of South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by HPV Application
16.23.1. Genital Warts
16.23.2. Genital Cancer
16.23.3. Epidermodysplasia Verrucifdormis
16.23.4. Oral Papillomas
16.24. Rest of South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Antiviral Drug
16.24.1. Ganciclovir/Valganciclovir
16.24.2. Foscarnet
16.24.3. Cidofovir
16.25. Rest of South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Forecast, by CMV Application
16.25.1. CMV Retinitis
16.25.2. Pneumonia
16.25.3. Gastrointestinal ulcers
16.25.4. Encephalitis
16.26. South America Human Papillomavirus and Cytomegalovirus Therapeutics Market Attractiveness Analysis
16.26.1. By HPV Drug Class
16.26.2. By HPV Application
16.26.3. By CMV Antiviral Drug
16.26.4. By CMV Application
16.27. PEST Analysis
16.28. Key Trends
16.29. Key Developments
17. Company Profiles
17.1. Market Share Analysis, by Company
17.2. Competition Matrix
17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
17.2.2. New Product Launches and Product Enhancements
17.2.3. Market Consolidation
17.2.3.1. M&A by Regions, Investment and Applications
17.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
17.3. Company Profiles: Key Players
17.3.1. Allergan
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategy
17.3.1.5. Recent Developments
17.3.1.6. Company Footprint
17.3.2. Bausch Health
17.3.3. GlaxoSmithKline
17.3.4. Lee's Pharmaceutical Holdings
17.3.5. Merck Sharp & Dohme
17.3.6. Fougera Pharmaceuticals
17.3.7. Clinigen Group plc.
17.3.8. Perrigo Company plc.
17.3.9. Roche Holding AG
17.3.10. Biotest AG
17.3.11. Fresenius Kabi
17.3.12. Valeant Pharmaceuticals
17.3.13. AbbVie, Inc.
17.3.14. Mylan N.V.
17.3.15. Teva Pharmaceutical Industries Ltd.
17.3.16. Clinigen Group plc
17.3.17. Cipla Inc.
18. Primary Key Insights